Evaluating BRAF and MEK Inhibitors to Treat Neuroblastoma

评估 BRAF 和 MEK 抑制剂治疗神经母细胞瘤的效果

• 批准号: 255034
• 负责人: Cook Elina K
• 金额: $ 1.27万
• 依托单位: Hospital for Sick Children (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2012
• 资助国家: 加拿大
• 起止时间: 2012-02-01 至 2013-02-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=255034&lang=en
• 关键词: Braf Inhibitors; Effector Concentrations; Mapk Signaling Pathway; Mek Inhibitors; Mouse Xenografts; Neuroblastoma; Paediatric Oncology; Shrna

Most patients with neuroblastoma (NB), a cancer of the nervous system, are children under the age of five. By the time NB is diagnosed, it has often metastasized and affords less than five years of life. Initially, a NB tumour may respond to aggressive ch

神经母细胞瘤(NB)是一种神经系统癌症，大多数患者都是5岁以下的儿童。当被诊断为NB时，它通常已经转移，并能承受不到五年的生命。最初，NB肿瘤可能对侵袭性CH有反应。